A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics
A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IBI112 in Participants With Psoriasis Who Were Treated With Biologics and Switched to IBI112
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
This PHASE2 trial investigates Psoriasis and is currently completed. Innovent Biologics (Suzhou) Co. Ltd. leads this study, which shows 7 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
May 2025 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Oct 2023 — Feb 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Aug 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Innovent Biologics (Suzhou) Co. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .